This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

57/100

✓ Peer-reviewed alzhub usefulness score 57 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 years have changed the way we think about AD. This review discusses some of the challenges to translating these basic molecular and cellular discoveries into clinical therapies. Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011). Alzheimer's disease: the challenge of the second century. Science translational medicine. https://doi.org/10.1126/scitranslmed.3002369

Vancouver

Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Science translational medicine. 2011. doi:10.1126/scitranslmed.3002369. PMID: 21471435.

BibTeX

@article{holtzman2011-21471435,
  author  = {Holtzman, D. M. and Morris, J. C. and Goate, A. M.},
  title   = {{Alzheimer's disease: the challenge of the second century}},
  journal = {Science translational medicine},
  year    = {2011},
  doi     = {10.1126/scitranslmed.3002369},
  pmid    = {21471435},
  url     = {https://doi.org/10.1126/scitranslmed.3002369}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: this is a narrative review. It summarises a field without a fixed search method, so it shows how authors read the evidence rather than measuring it. Use it to find the primary studies, not as a result in itself.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.

Why it matters

This review states that there is currently no effective treatment that delays the onset or slows the progression of Alzheimer's disease. It suggests that if the disease is detected before symptoms appear, treatments based on knowledge of its underlying pathogenesis might be effective, but this is a proposal rather than a demonstrated treatment.

New to this subject? Start with our plain-English guide: Alzheimer's in numbers →

Study details

Evidence strengthLow

How this study scored 57/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Science translational medicine)
Journal's citation record	3 / 4	Science Translational Medicine: journal h-index 365 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2011 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	7 / 7	Cited 1,424 times (OpenAlex, 2026-10-10)
Citations per year	5 / 5	83.8 citations a year over 17 year(s) since 2011
Impact for its field and year	6 / 6	Cited 53.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	4 / 6	Cited by 57 other studies in this library
Still being cited	4 / 4	Cited 226 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Alison Goate: h-index 156 (OpenAlex, whole career)
Institution's track record	2 / 3	Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 21471435)
Free to read	0 / 2	Behind a paywall — scores zero
Total	57 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 64.

Later studies that cite this one

57 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in How common it is from nearby years

Also in How common it is

80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.

Similar studies

More on How common it is

See all studies in How common it is →